• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Advancing clinical-basic-clinical research: exploring novel immunotargets for ovarian cancer.

作者信息

Gu Yuanzhuo, Zhang Long, Lv Weiguo

机构信息

Department of Gynecological Oncology, Women's Hospital, Zhejiang University School of Medicine, 310006, Hangzhou, China.

MOE Key Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, 310058, Hangzhou, China.

出版信息

Signal Transduct Target Ther. 2024 Sep 30;9(1):260. doi: 10.1038/s41392-024-01970-6.

DOI:10.1038/s41392-024-01970-6
PMID:39349435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442627/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e122/11442627/487446a17af8/41392_2024_1970_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e122/11442627/487446a17af8/41392_2024_1970_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e122/11442627/487446a17af8/41392_2024_1970_Fig1_HTML.jpg

相似文献

1
Advancing clinical-basic-clinical research: exploring novel immunotargets for ovarian cancer.推进临床-基础-临床研究：探索卵巢癌的新型免疫靶点。
Signal Transduct Target Ther. 2024 Sep 30;9(1):260. doi: 10.1038/s41392-024-01970-6.
2
Organoid of ovarian cancer: genomic analysis and drug screening.卵巢癌类器官：基因组分析与药物筛选。
Clin Transl Oncol. 2020 Aug;22(8):1240-1251. doi: 10.1007/s12094-019-02276-8. Epub 2020 Jan 14.
3
Immunotherapy for ovarian cancer: what are the targets of the future?卵巢癌免疫疗法：未来的靶点有哪些？
Future Oncol. 2015;11(9):1293-6. doi: 10.2217/fon.15.44.
4
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer.卵巢癌长期存活者肿瘤微环境的免疫和分子特征
J Clin Invest. 2024 Oct 29;134(24):e179501. doi: 10.1172/JCI179501.
5
Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?卵巢癌免疫治疗的前景与挑战——肿瘤微环境能给我们带来什么启示？
Int Rev Immunol. 2011 Apr-Jun;30(2-3):67-70. doi: 10.3109/08830185.2011.571731.
6
Multi-omics analysis and experiments uncover the link between cancer intrinsic drivers, stemness, and immunotherapy in ovarian cancer with validation in a pan-cancer census.多组学分析与实验揭示了卵巢癌中癌症内在驱动因素、干性与免疫治疗之间的联系，并在泛癌普查中得到验证。
Front Immunol. 2025 May 8;16:1549656. doi: 10.3389/fimmu.2025.1549656. eCollection 2025.
7
The biological roles of CD47 in ovarian cancer progression.CD47 在卵巢癌进展中的生物学作用。
Cancer Immunol Immunother. 2024 Jun 4;73(8):145. doi: 10.1007/s00262-024-03708-3.
8
Multi-omics analysis and experiments uncover the function of cancer stemness in ovarian cancer and establish a machine learning-based model for predicting immunotherapy responses.多组学分析与实验揭示了卵巢癌中癌症干性的功能，并建立了一种基于机器学习的模型来预测免疫治疗反应。
Front Immunol. 2024 Dec 11;15:1486652. doi: 10.3389/fimmu.2024.1486652. eCollection 2024.
9
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?复发性卵巢癌的免疫治疗：是进一步解决问题的方法，还是引人注目的策略？
Expert Opin Biol Ther. 2014 Jan;14(1):103-14. doi: 10.1517/14712598.2014.859671.
10
HBO1 determines epithelial-mesenchymal transition and promotes immunotherapy resistance in ovarian cancer cells.HBO1决定卵巢癌细胞的上皮-间质转化并促进免疫治疗抗性。
Cell Oncol (Dordr). 2025 Apr 14. doi: 10.1007/s13402-025-01055-8.

引用本文的文献

1
Biochemical impact and therapeutic efficacy of laparoscopic surgery in early-stage ovarian cancer: Modulation of vascular endothelial growth factor and tumor markers.腹腔镜手术对早期卵巢癌的生化影响及治疗效果：血管内皮生长因子和肿瘤标志物的调节
J Med Biochem. 2025 Jun 13;44(3):432-437. doi: 10.5937/jomb0-56011.

本文引用的文献

1
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.新辅助 PARPi 或化疗在卵巢癌中告知靶向效应 Treg 细胞同源重组缺陷肿瘤。
Cell. 2024 Sep 5;187(18):4905-4925.e24. doi: 10.1016/j.cell.2024.06.013. Epub 2024 Jul 5.
2
Global epidemiology of epithelial ovarian cancer.上皮性卵巢癌的全球流行病学。
Nat Rev Clin Oncol. 2024 May;21(5):389-400. doi: 10.1038/s41571-024-00881-3. Epub 2024 Mar 28.
3
Frequency of peripheral PD-1regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.
外周 PD-1 调节性 T 细胞的频率与上皮性卵巢癌患者接受 PARP 抑制剂维持治疗的反应相关。
Br J Cancer. 2023 Nov;129(11):1841-1851. doi: 10.1038/s41416-023-02455-z. Epub 2023 Oct 11.
4
Understanding and overcoming resistance to PARP inhibitors in cancer therapy.理解和克服癌症治疗中对 PARP 抑制剂的耐药性。
Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
5
It's Time to Reverse our Thinking: The Reverse Translation Research Paradigm.是时候扭转我们的思维了：反向翻译研究范式。
Clin Transl Sci. 2018 Mar;11(2):98-99. doi: 10.1111/cts.12538. Epub 2018 Feb 9.